FABP3 and Alzheimer disease: FABP3 levels are increased in the cerebrospinal fluid (CSF) of patients with AD compared to those in normal individuals [9–16], and it has been identified as an AD biomarker using multiplex platforms and validated in the Alzheimer’s Disease Neuroimaging Initiative database [17–20].